The Mexico Fund, Inc. Pays Distribution WASHINGTON,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
70
The Mexico Fund, Inc. Pays Distribution

WASHINGTON, DC--(Marketwired - Apr 28, 2017) -  The Mexico Fund, Inc. (NYSE: MXF) announced that it will pay today a distribution of $0.1300 per share in cash to stockholders of record as of April 20, 2017, according to the Fund's Managed Distribution Plan (MDP).

As a general matter, the amount of distributable income for each fiscal period depends on the aggregate gains and losses realized by the Fund during the entire year. Distributions may consist of net investment income, capital gains and return of capital, but the character of these distributions cannot be determined until after the end of the Fund's fiscal year. 

However, under the Investment Company Act of 1940, the Fund is required to indicate the source of each distribution to stockholders. The following table sets forth an estimate of the sources of the April 28, 2017 distribution and distributions paid in the current fiscal year:

         
Distribution Estimates   April 2017   Fiscal Year-to-date (YTD)1
Source   Per Share Amount   Percent of Current Distribution   Per Share Amount   Percent of Fiscal Year Distributions
Net Investment Income   -   -   -   -
Net Realized Short-Term Capital Gains   -   -   -   -
Net Realized Long-Term Capital Gains   -   -   -   -
Return of Capital   $0.1300   100.00%   $0.2715   100.00%
Total Distribution   $0.1300   100.00%   $0.2715   100.00%
                 

Information regarding the Fund's performance and distribution rates is set forth below:

Average Annual Total Return for the 5-year period ended on March 31, 20172   1.71%
Current Annualized Distribution Rate (current fiscal year)3   1.84%
Current Fiscal Year Cumulative Total Return4   1.12%
Cumulative Distribution Rate (current fiscal year)5   0.76%

1 The Fund's current fiscal year began on November 1, 2016.

2 Average Annual Total Return represents the simple arithmetic average of the Annual NAV Total Returns of the Fund for the last five years. Annual NAV Total Return is the percentage change in the Fund's NAV over a year including distributions paid and assuming reinvestment of those distributions.

3 The Current Annualized Distribution Rate is the Cumulative Distribution Rate as of March 31, 2017, annualized as a percentage of the Fund's NAV at the same date.

4 Current Fiscal Year Cumulative Total Return is the percentage change in the Fund's NAV from November 1, 2016, through March 31, 2017, including distributions paid and assuming reinvestment of those distributions.

5 Cumulative Distribution Rate for the Fund's current fiscal period (November 1, 2016, through March 31, 2017) measured on the dollar value of distributions in the period as a percentage of the Fund's NAV as of March 31, 2017.

You should not draw any conclusions about the Fund's investment performance from the amount of this distribution or from the terms of the Fund's MDP.

The amounts and sources of distributions reported above are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for accounting and tax reporting purposes will depend upon the Fund's investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report the distribution for federal income tax purposes.

For further information, contact the Fund's Investor Relations office at +52-55-9138-3350, or by email at investor-relations@themexicofund.com

The Mexico Fund, Inc. is a non-diversified closed-end management investment company with the investment objective of long-term capital appreciation through investments in securities, primarily equity, listed on the Mexican Stock Exchange. The Fund provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.

This press release may contain certain forward-looking statements regarding future circumstances. These forward-looking statements are based upon the Fund's current expectations and assumptions and are subject to various risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements including, in particular, the risks and uncertainties described in the Fund's filings with the Securities and Exchange Commission. Actual results, events, and performance may differ. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Fund undertakes no obligation to release publicly any revisions to these forward looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. The inclusion of any statement in this release does not constitute an admission by The Mexico Fund or any other person that the events or circumstances described in such statement are material.

CONTACT: Alberto Gomez Pimienta The Mexico Fund, Inc. +52-55-9138-3350 CONTACT: Patricia Baronowski Pristine Advisers, LLC (631) 756-2486

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Compass Unveiled: Power Revolution in Private Equity

Updated Category News Views 5

AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
HTX's Strategic Moves in Pakistan: A Crypto Frontier

Updated Category News Views 5

Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 8

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
AI-Driven Lumi Transforms Car Dealership Interactions

Updated Category News Views 7

Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...

Continue Reading
The Chemical Industry and EPA: A Broken System?

Updated Category News Views 3

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Continue Reading
Leapora's Taskeen: Redefining Task Accountability

Updated Category News Views 2

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Succession Planning in Turmoil: Only 42% Ready

Updated Category News Views 5

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

Continue Reading

Top 5 Most Recently Viewed Articles

In-Silico Clinical Trials Expected to Surge to $6.39 Billion

Updated Category News Views 196

In-Silico Clinical Trials Market Overview The in-silico clinical trials market is witnessing substantial growth, projected to reach USD 6.39 billion in the near future. This transformation reflects a significant shift in how pharmaceutical and medical technology companies approach drug development and clinical evaluation. By leveraging advanced digital technologies,...

Continue Reading
Longeveron Inc. Announces Significant Leadership Changes

Updated Category News Views 162

Longeveron Inc. Leadership Evolution Longeveron Inc. has recently made pivotal updates to its leadership team, signaling significant strategic shifts within the company. Than Powell is stepping up as the Interim CEO, while Dr. Joshua Hare, a cornerstone of the company, takes on the role of Executive Chairman of the Board. These changes come as the company aims to enhance...

Continue Reading
Aebi Schmidt Group's Growth Strategy Post-Merger Unveiled

Updated Category News Views 218

Aebi Schmidt Group's Strategic Vision After Merger Aebi Schmidt Group is actively trading under the ticker symbol "AEBI" after completing an exciting merger with The Shyft Group. The organization is well-positioned with a robust balance sheet, focusing on executing its post-merger strategies effectively. Amidst a dynamic operating environment, the company's commitment to...

Continue Reading
Unibail-Rodamco-Westfield Achieves Top ‘A’ Rating in Sustainability

Updated Category News Views 373

Unibail-Rodamco-Westfield's Commitment to Sustainability Unibail-Rodamco-Westfield, often abbreviated as URW, has accomplished an impressive feat by receiving a top ‘A’ rating from CDP for the seventh consecutive year. This recognition is a testament to the company's continuous efforts and transparent actions in combating climate change, all structured under its...

Continue Reading
Genstar Capital Hires Industry Veteran John Kufner for Advisory

Updated Category News Views 280

Big Moves in Private Equity: Genstar's New Addition What’s the deal here? Genstar Capital, that powerhouse in private equity, just scored big by bringing John Kufner on board as part of their Strategic Advisory Board. This isn’t just another hire; it's a strategic chess move. Kufner isn’t your run-of-the-mill executive—he's been around the block more than a few...

Continue Reading